Profile data is unavailable for this security.
About the company
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing treatments for serious diseases. The Company’s portfolio includes novel soluble guanylate cyclase (sGC) stimulators, namely praliciguat and olinciguat, as well as multiple research stage molecules. Praliciguat is a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. Olinciguat is a vascular sGC stimulator that the Company intends to out-license for cardiovascular diseases. The Company operates through the human therapeutics segment. The Company is focused on identifying non-sGC stimulator assets within the central nervous system (CNS) therapeutic area to build a new portfolio. The Company is also evaluating other activities aimed at enhancing shareholder value, which potentially include collaborations, licenses, mergers, acquisitions and/or other targeted investments.
- Revenue in USD (TTM)0.00
- Net income in USD-10.95m
- Incorporated2018
- Employees1.00
- LocationCyclerion Therapeutics Inc301 Binney StreetCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 621-7722
- Websitehttps://www.cyclerion.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ayala Pharmaceuticals Inc | 13.00k | -48.07m | 7.29m | 20.00 | -- | -- | -- | 560.79 | -7.46 | -7.46 | 0.0022 | -2.06 | -- | -- | -- | 650.00 | -- | -- | -- | -- | 0.00 | -- | -369,784.60 | -- | -- | -2.31 | -- | -- | -- | -- | -- | -- | -- | -- |
| Virios Therapeutics Inc | 0.00 | -5.07m | 7.36m | 4.00 | -- | -- | -- | -- | -0.2673 | -0.2673 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 56.76 | -- | -- | -- |
| Healthy Extracts Inc | 2.56m | -2.76m | 7.41m | -- | -- | 48.86 | -- | 2.89 | -0.9512 | -0.9512 | 0.8819 | 0.0512 | 0.9428 | 0.5035 | 32.10 | -- | -101.47 | -53.78 | -375.65 | -146.65 | 68.46 | 45.68 | -107.63 | -87.53 | 0.1293 | -2.22 | 0.879 | -- | 10.41 | 105.93 | -151.54 | -- | -- | -- |
| Geovax Labs Inc | 0.00 | -27.78m | 7.66m | 17.00 | -- | 128.85 | -- | -- | -14.42 | -14.42 | 0.00 | 0.0235 | 0.00 | -- | -- | 0.00 | -180.60 | -108.34 | -242.41 | -147.24 | -- | -- | -- | -1,842.93 | -- | -- | 0.00 | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Cadrenal Therapeutics Inc | -100.00bn | -100.00bn | 7.68m | 3.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| National Graphite Corp | 0.00 | -1.97m | 7.72m | 0.00 | -- | -- | -- | -- | -0.0221 | -0.0221 | 0.00 | -0.0193 | 0.00 | -- | -- | -- | -11,014.44 | -212.13 | -- | -6,295.18 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -1,432.70 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 0.00 | -10.95m | 7.78m | 1.00 | -- | 0.723 | -- | -- | -4.38 | 0.2904 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -95.95 | -72.70 | -158.12 | -86.96 | -- | -- | -- | -2,565.62 | -- | -- | 0.00 | -- | -100.00 | -- | 30.98 | -- | -- | -- |
| Weed Inc | 0.00 | -5.19k | 8.03m | 2.00 | -- | 74.68 | 204.96 | -- | -0.00001 | -0.00001 | 0.00 | 0.0009 | 0.00 | -- | -- | 0.00 | -0.4942 | -385.93 | -9.56 | -822.37 | -- | -- | -- | -- | -- | -23.03 | 0.5461 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
| 4Cable TV International Inc | 758.68k | -3.14m | 8.05m | 0.00 | -- | -- | -- | 10.61 | -0.0624 | -0.0624 | 0.0157 | -0.0412 | 1.07 | 1.84 | 25.22 | -- | -441.73 | -82.30 | -- | -308.10 | 29.92 | -- | -414.41 | -47.62 | 0.0064 | -0.5271 | -- | -- | -0.0914 | -- | -731.54 | -- | -- | -- |
| ABVC Biopharma Inc | 25.37k | -12.62m | 8.24m | 16.00 | -- | 1.04 | -- | 324.66 | -2.37 | -2.37 | 0.0043 | 0.7284 | 0.002 | -- | 0.0673 | 1,585.63 | -103.15 | -103.38 | -189.31 | -231.54 | -854.20 | 76.25 | -51,218.29 | -2,019.89 | -- | -3.19 | 0.1853 | -- | -84.28 | 85.39 | 35.97 | -- | -- | -- |
| Moleculin Biotech Inc | 0.00 | -26.82m | 8.34m | 18.00 | -- | 0.3866 | -- | -- | -12.94 | -12.94 | 0.00 | 9.34 | 0.00 | -- | -- | 0.00 | -65.50 | -46.84 | -75.07 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
| Endexx Corp | 4.64m | 6.93m | 8.35m | -- | 1.24 | -- | 1.41 | 1.80 | 0.0133 | 0.0133 | 0.0091 | -0.0255 | 0.6773 | 4.37 | 13.54 | -- | 86.51 | -- | -- | -- | 28.73 | -- | 127.74 | -- | 0.0664 | -- | -- | -- | 228.66 | -- | 28.26 | -- | -- | -- |
| BioNexus Gene Lab Corp | 9.78m | -2.66m | 8.40m | 30.00 | -- | 0.8987 | -- | 0.859 | -0.14 | -0.14 | 0.651 | 0.5289 | 1.01 | 8.55 | 5.80 | -- | -27.53 | -3.83 | -33.16 | -5.02 | 13.56 | 14.55 | -27.25 | -3.04 | 3.98 | -162.45 | 0.00 | -- | -10.60 | 115.07 | -638.56 | -- | 30.40 | -- |
Data as of Jun 25 2024. Currency figures normalised to Cyclerion Therapeutics Inc's reporting currency: US Dollar USD
39.46%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Slate Path Capital LPas of 31 Mar 2024 | 357.88k | 13.21% |
| MFN Partners Management LPas of 31 Mar 2024 | 169.46k | 6.25% |
| Tyndall Management LLCas of 31 Mar 2024 | 164.78k | 6.08% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 162.32k | 5.99% |
| Invus Public Equities Advisors LLCas of 31 Mar 2024 | 138.96k | 5.13% |
| Geode Capital Management LLCas of 31 Mar 2024 | 32.08k | 1.18% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 23.49k | 0.87% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 17.17k | 0.63% |
| UBS Securities LLCas of 31 Mar 2024 | 2.52k | 0.09% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 649.00 | 0.02% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
